How long can one live with urothelial cancer?

Survival time for urothelial cancer varies depending on a variety of factors, including the stage of the cancer, some of the patient's physical conditions, treatment methods, and whether metastasis has occurred. The following is relevant information for reference:

1.Survival period of early urethral carcinoma: If urothelial cancer is detected in the early stage (I stage) and has not yet invaded the muscle layer, the patient usually has a better prognosis. After transurethral resection of bladder tumors (TURBT) and subsequent adjuvant treatment, the 5 annual survival rate can reach 70%-90%. This situation mainly depends on the patient's tolerance of the treatment and the risk management of the cancer switch.

2. Myometrial ductal urothelial carcinoma: When it invades the muscular layer of the vagina ( Stage II or higher), the survival rate will be significantly reduced. For patients who undergo radical vaginal resection or combined chemotherapy, the 5 annual survival rate is about 40%-60%. For localized disease, aggressive surgical impact and chemotherapy can significantly prolong patient survival.

3. Metastatic urothelial cancer: Metastatic urothelial cancer (Stage IV) usually requires treatment for survival. Median survival for patients treated for urothelial cancer is typically less than1 years. For patients who use immunotherapy, therapy or chemotherapy, the median survival time can be extended to 1-2 years, and some patients who are sensitive to treatment can even survive for more than 3 years, but the possibility of complete cure is low.

The patient's age, health status, treatment tolerance, and experience of the treatment team will all affect survival time. In recent years, with the introduction of immune checkpoint response (such as PD-1/PD-L1 inhibition) and key drugs, the long-term survival of some patients has been improved. Therefore, timely medical treatment and standardized treatment are crucial to prolonging survival.

(Click to view an introduction to drugs for the treatment of urothelial cancer.)

xa0

Reference materials

American Cancer Society (American Cancer Society):https ://www .cancer .org